Financials

%ChgLast 12MReverse

	FY202312/31/2023	FY202412/31/2024	FY202512/31/2025	Last 12M03/31/2026
Cash and Cash Equivalents	226.7	189.2	155.5	134.7
Short Term Investments	685.5	412.3	294.4	241.3
Cash and Short Term Investments	912.2	601.5	449.9	376.0
Net Receivables	36.5	8.5	9.5	9.1
Inventory	-	-	-	-
Other Current Assets	49.7	29.8	68.4	81.3
Total Current Assets	998.3	639.9	527.7	466.4
Property, Plant & Equipment	148.1	246.7	123.6	113.1
Long Term Investments	154.5	44.3	35.5	38.0
Other Non-Current Assets	-	260.2	155.3	141.3
Total Non-Current Assets	302.6	551.2	314.4	292.3
Total Assets	1,301.0	1,191.0	842.1	758.8
Account Payables	7.5	14.6	20.3	18.8
Short Term Debt	-	-	-	-
Deferred Revenue	22.1	20.7	7.3	0.6
Other Current Liabilities	6.9	55.4	23.1	9.3
Total Current Liabilities	115.2	110.9	103.9	76.4
Long Term Debt	-	-	66.8	61.4
Other Non-Current Liabilities	38.9	-	-	-
Total Non-Current Liabilities	135.6	208.2	66.8	61.4
Total Liabilities	250.8	319.1	170.7	137.8
Common Stock	0.0	0.0	0.0	0.0
Retained Earnings	-1,658.4	-2,177.4	-2,590.1	-2,686.3
Total Stockholders Equity	1,050.2	872.0	671.4	620.9
Total Liabilities and Equity	1,301.0	1,191.0	842.1	758.8

Intellia Therapeutics, Inc.(NTLA US)